<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589316</url>
  </required_header>
  <id_info>
    <org_study_id>2186.00</org_study_id>
    <secondary_id>NCI-2010-00404</secondary_id>
    <secondary_id>2186.00p</secondary_id>
    <secondary_id>2186.00</secondary_id>
    <secondary_id>P01CA044991</secondary_id>
    <secondary_id>RG1707019</secondary_id>
    <nct_id>NCT00589316</nct_id>
  </id_info>
  <brief_title>Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of iodine I 131monoclonal antibody&#xD;
      BC8 when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation,&#xD;
      and donor bone marrow transplant, and to see how well they work in treating patients with&#xD;
      acute myeloid leukemia or acute lymphoblastic leukemia that has spread to nearby or other&#xD;
      places in the body (advanced), or high-risk myelodysplastic syndrome. Giving chemotherapy&#xD;
      drugs, such as fludarabine phosphate and cyclophosphamide, and total-body irradiation before&#xD;
      a donor bone marrow transplant helps stop the growth of cancer or abnormal cells and helps&#xD;
      stop the patient's immune system from rejecting the donor's stem cells. Also, radiolabeled&#xD;
      monoclonal antibodies, such as iodine I 131 monoclonal antibody BC8, can find cancer cells&#xD;
      and carry cancer-killing substances to them without harming normal cells. When the healthy&#xD;
      stem cells from a donor are infused into the patient they may help the patient's bone marrow&#xD;
      make stem cells, red blood cells, white blood cells, and platelets. Sometimes the&#xD;
      transplanted cells from a donor can make an immune response against the body's normal cells.&#xD;
      Giving cyclophosphamide together with mycophenolate mofetil and tacrolimus after the&#xD;
      transplant may stop this from happening. Giving a radiolabeled monoclonal antibody together&#xD;
      with donor stem cell transplant, fludarabine phosphate, cyclophosphamide, mycophenolate&#xD;
      mofetil, and tacrolimus may be an effective treatment for advanced acute myeloid leukemia,&#xD;
      acute lymphoblastic leukemia, or myelodysplastic syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximum tolerated dose of radiation delivered via 131 I-BC8 antibody&#xD;
      (iodine I 131 monoclonal antibody BC8) when combined with pre- and post-transplant&#xD;
      cyclophosphamide (CY), fludarabine phosphate (FLU), 2 Gy total-body irradiation (TBI),&#xD;
      tacrolimus, mycophenolate mofetil (MMF), and a haploidentical allogeneic hematopoietic marrow&#xD;
      transplant in patients who have advanced acute myeloid leukemia (AML), acute lymphoblastic&#xD;
      leukemia (ALL), or high risk myelodysplastic syndromes (MDS).&#xD;
&#xD;
      II. To estimate rates of immune reconstitution, engraftment, and donor chimerism resulting&#xD;
      from this combined preparative regimen.&#xD;
&#xD;
      III. To determine rates of disease relapse, acute graft-versus-host disease (GVHD), and day&#xD;
      100 disease-free survival in patients receiving 131 I-BC8 antibody (Ab) combined with CY,&#xD;
      FLU, 2 Gy TBI, tacrolimus, MMF, and human leukocyte antigen (HLA)-haploidentical allogeneic&#xD;
      hematopoietic cell transplant (HCT).&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of iodine I 131 monoclonal antibody BC8.&#xD;
&#xD;
      RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via&#xD;
      central line on day -14.&#xD;
&#xD;
      NONMYELOABLATIVE CONDITIONING: Patients receive FLU intravenously (IV) over 30 minutes on&#xD;
      days -6 to -2 and CY IV over 1 hour on days -6 and -5. Patients undergo TBI on day -1.&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.&#xD;
&#xD;
      POST-TRANSPLATATION IMMUNOSUPPRESSION: Patients receive CY IV over 1-2 hours on day 3, MMF IV&#xD;
      or orally (PO) thrice daily (TID) on days 4 to 35, and tacrolimus IV over 1-2 hours or PO on&#xD;
      days 4 to 180 with taper on day 84.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 6, 9, 12, 18, and 24 months,&#xD;
      and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to loss of funding&#xD;
  </why_stopped>
  <start_date type="Actual">October 5, 2007</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of 131 I-BC8 antibody defined as the dose that is associated with a true dose limiting toxicity (DLT) rate of 25%, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3</measure>
    <time_frame>Up to 30 days post-transplant</time_frame>
    <description>A DLT will be defined as a grade III/IV (Bearman scale) toxicity that occurs within 30 days following transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of acute GVHD</measure>
    <time_frame>Through day 100</time_frame>
    <description>Graded according to the established criteria at the Fred Hutchinson Cancer Research Center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of disease relapse</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of disease-free survival</measure>
    <time_frame>Through day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of donor chimerism</measure>
    <time_frame>Through day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of engraftment</measure>
    <time_frame>Through day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of immune reconstitution</measure>
    <time_frame>Through day 100</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>CD45-Positive Neoplastic Cells Present</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <condition>Refractory Anemia With Excess Blasts</condition>
  <condition>Refractory Anemia With Ring Sideroblasts</condition>
  <condition>Refractory Cytopenia With Multilineage Dysplasia</condition>
  <condition>Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts</condition>
  <arm_group>
    <arm_group_label>Treatment (chemo, TBI, transplant, immunosuppression)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via central line on day -14.&#xD;
NONMYELOABLATIVE CONDITIONING: Patients receive FLU IV over 30 minutes on days -6 to -2 and CY IV over 1 hour on days -6 and -5. Patients undergo TBI on day -1.&#xD;
TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.&#xD;
POST-TRANSPLATATION IMMUNOSUPPRESSION: Patients receive CY IV over 1-2 hours on day 3, MMF IV or PO TID on days 4 to 35, and tacrolimus IV over 1-2 hours or PO on days 4 to 180 with taper on day 84.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Given via central line</description>
    <arm_group_label>Treatment (chemo, TBI, transplant, immunosuppression)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, TBI, transplant, immunosuppression)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, TBI, transplant, immunosuppression)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Iodine I 131 Monoclonal Antibody BC8</intervention_name>
    <description>Given IV (dosimetry dose) or via central line (therapeutic dose)</description>
    <arm_group_label>Treatment (chemo, TBI, transplant, immunosuppression)</arm_group_label>
    <other_name>I 131 MOAB BC8</other_name>
    <other_name>I 131 Monoclonal Antibody BC8</other_name>
    <other_name>iodine I 131 MOAB BC8</other_name>
    <other_name>Iomab-B</other_name>
    <other_name>MOAB BC8, iodine I 131</other_name>
    <other_name>monoclonal antibody BC8, iodine I 131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemo, TBI, transplant, immunosuppression)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (chemo, TBI, transplant, immunosuppression)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (chemo, TBI, transplant, immunosuppression)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (chemo, TBI, transplant, immunosuppression)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced AML or ALL defined as beyond first remission, primary&#xD;
             refractory disease, or evolved from myelodysplastic or myeloproliferative syndromes;&#xD;
             or patients with MDS expressed as refractory anemia with excess blasts (RAEB),&#xD;
             refractory cytopenia with multilineage dysplasia (RCMD), RCMD with ringed sideroblasts&#xD;
             (RCMD-RS), or chronic myelomonocytic leukemia (CMML)&#xD;
&#xD;
          -  Patients not in remission must have cluster of differentiation (CD)45-expressing&#xD;
             leukemic blasts; patients in remission do not require phenotyping and may have&#xD;
             leukemia previously documented to be CD45 negative (because in remission patients,&#xD;
             virtually all antibody binding is to non-malignant cells which make up &gt;= 95% of&#xD;
             nucleated cells in the marrow)&#xD;
&#xD;
          -  Patients should have a circulating blast count of less than 10,000/mm^3 (control with&#xD;
             hydroxyurea or similar agent is allowed)&#xD;
&#xD;
          -  Patients must have a creatinine clearance greater than 50/ml per minute by the&#xD;
             following formula (test must be performed within 28 days prior to registration):&#xD;
&#xD;
               -  Creatinine clearance (CrCl) = (140-age) (Wt in Kg) x 0.85 (female) OR 1.0&#xD;
                  (male)/72 x serum Cr&#xD;
&#xD;
          -  Bilirubin &lt; 2 times the upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2 times the&#xD;
             upper limit of normal&#xD;
&#xD;
          -  Karnofsky score &gt;= 70 or Eastern Cooperative Oncology Group (ECOG) =&lt; 2&#xD;
&#xD;
          -  Patients must have an expected survival of &gt; 60 days and must be free of active&#xD;
             infection&#xD;
&#xD;
          -  Patients must have a related donor who is identical for one human leukocyte antigen&#xD;
             (HLA) haplotype and mismatched at the HLA-A, -B or class II, DR beta 1 (DRB1) loci of&#xD;
             the unshared haplotype with the exception of single HLA-A, -B or DRB1 mismatches&#xD;
&#xD;
          -  DONOR: Related donor who is identical for one HLA haplotype and mismatched at the&#xD;
             HLA-A, -B, or DRB1 loci of the unshared haplotype with the exception of single HLA-A,&#xD;
             -B, or DRB1 mismatches&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Circulating antibody against mouse immunoglobulin (HAMA)&#xD;
&#xD;
          -  Prior radiation to maximally tolerated levels to any critical normal organ&#xD;
&#xD;
          -  Cross-match positive with donor&#xD;
&#xD;
          -  Patients may not have symptomatic coronary artery disease and may not be on cardiac&#xD;
             medications for anti-arrhythmic or inotropic effects&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 35%&#xD;
&#xD;
          -  Corrected diffusion capacity of carbon monoxide (DLCO) &lt; 35% and/or receiving&#xD;
             supplemental continuous oxygen&#xD;
&#xD;
          -  Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of&#xD;
             portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy,&#xD;
             uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the&#xD;
             prothrombin time, ascites related to portal hypertension, bacterial or fungal liver&#xD;
             abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease&#xD;
&#xD;
          -  Patients who are known seropositive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Perceived inability to tolerate diagnostic or therapeutic procedures, particularly&#xD;
             treatment in radiation isolation&#xD;
&#xD;
          -  Central nervous system (CNS) involvement with disease refractory to intrathecal&#xD;
             chemotherapy and/or standard cranial-spinal radiotherapy&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin&#xD;
             positive [b-HCG+]) or breast feeding&#xD;
&#xD;
          -  Fertile men and women unwilling to use contraceptives during and for 12 months&#xD;
             post-transplant&#xD;
&#xD;
          -  Inability to understand or give an informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnnie Orozco</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

